Retatrutide

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameRetatrutide
Drug Alias NameGGG Tri-agonist (Lilly)GLP-1/GIP/glucagon tri-agonist (Lilly)LY-3437943
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon receptor
Therapy Area/IndicationsLow Back PainOverweightObesity +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesHudson BiotechEli Lilly And CompanyLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLow Back PainOverweightObesity +[14] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A